Infections in patients with rheumatoid arthritis treated with biologic agents.
about
Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitisNew insights into the impact of neuro-inflammation in rheumatoid arthritisWhat is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritisEtanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.Biologics registers in RA: methodological aspects, current role and future applications.Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims databaseEffect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria.Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database.Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project.Ten years with biologics: to whom do data on effectiveness and safety apply?Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.Initiation of rheumatoid arthritis treatments and the risk of serious infections.Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases.A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesSafety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients.Patients with arthritis undergoing surgery: how should we manage tumour necrosis factor blocking agents perioperatively?-A systematic literature review.Abatacept treatment for rheumatoid arthritisUpdate on the treatment of ankylosing spondylitis.Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of RheumatologyCrosstalk between sentinel and helper macrophages permits neutrophil migration into infected uroepithelium.TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritisInteractions between the immune and nervous systems in pain.Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register.The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with speciaInfliximab: 12 years of experienceThe comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agentsParadoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-α inhibitor: a case reportA prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors.
P2860
Q26774173-0A4D7724-97AE-4A33-AFA4-F19087E66796Q27023946-0ED235DA-C8BF-42D9-AAE5-65DABF09016FQ28074148-32DBE0F1-8140-4FE8-ACBC-8BC9E2DA2A0CQ28751012-99B8B96A-8A8C-4179-BB88-23B6739FE81CQ30009390-09C03D84-1AE4-4BCE-84D9-9A135FBDC94DQ30234303-9A239E60-F25D-48B3-96BF-8E59C023361EQ30240183-EA0B3997-EDE9-4530-AB45-2597B45E07D2Q30680371-57EE5BF0-D8D9-4FEC-B297-3CD4A0992A85Q30717002-F81E9291-A228-47EE-ABF2-3F72B20CB85EQ30990764-29DDF367-F91D-405D-99F9-E98C6EB0B187Q31107094-45F8380A-823A-480C-BB86-CC6E521C0CD7Q31122982-1238D6D8-B8F3-4E9F-9524-4F684C3FEF3AQ31123685-52BF221A-F2C0-4FC6-92AF-93514C13EB46Q31151183-4438D05C-50D8-46BD-BBD3-BE173B482DA6Q33315300-EF15374C-4020-49EA-8DED-B72A55941295Q33529391-792E16D7-CCE4-4105-9860-E7BF33A27A07Q33573112-E816EB42-8957-4420-890A-8F41437899E6Q33749195-3E9110F7-69A6-4975-86BA-A2878009D295Q33778719-4EB3278D-90BE-4602-BC16-D78FBD7042B7Q33819684-41DBB575-D0F8-4854-8127-B7712F36E5D8Q33923452-1FA68ADF-C097-45E3-8A42-86E5682C3680Q34019267-ECF23528-E264-48F1-A582-04CC08DE930FQ34065002-ACB2C150-0E35-4BFB-95B1-81CB34014968Q34216770-6BB3A6F2-EA74-4BA1-AFCC-8AFF7ABCF147Q34413239-14077B28-AE95-4FC8-817A-E969C20D8350Q34504816-9711360F-DE8A-44FD-AC4A-F722658A77E5Q34588972-7A4A482F-0313-4EDD-9F51-9873CC7B4031Q34592673-674CA51E-1EE5-483D-863B-F8C472D13FEFQ34641300-9CC8D498-8563-4E1D-8F28-71C23A50EA6AQ34643625-B1FAB633-54D0-4FF7-B983-D0A3D31B753BQ34792330-7B621AFE-1DEB-4281-9061-73062249918BQ34799654-FAD68E56-6AE2-48A4-97E8-649A4DE8C758Q34818636-B3D6E51F-DD67-49A7-BC10-FCDC6B31D017Q34897423-AEAB60E4-FA8F-4B30-8C72-7611848E5202Q34984568-3A246B6F-83E2-4960-B8C7-D2F43278E89AQ35018415-64AA0245-E6EC-4E2F-AA10-FE2848225B52Q35070446-C5250BE3-4AEF-44A2-9375-D807B4257A73Q35082559-E2F28958-32D0-4484-A4EE-770782BF4433Q35103988-6B31A4F2-D736-44B9-9359-FD4A0A5803F4Q35152199-2744A06A-AFB1-46E5-BAD1-4EF556D7C4E4
P2860
Infections in patients with rheumatoid arthritis treated with biologic agents.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Infections in patients with rheumatoid arthritis treated with biologic agents.
@en
Infections in patients with rheumatoid arthritis treated with biologic agents.
@nl
type
label
Infections in patients with rheumatoid arthritis treated with biologic agents.
@en
Infections in patients with rheumatoid arthritis treated with biologic agents.
@nl
prefLabel
Infections in patients with rheumatoid arthritis treated with biologic agents.
@en
Infections in patients with rheumatoid arthritis treated with biologic agents.
@nl
P2093
P356
P1476
Infections in patients with rheumatoid arthritis treated with biologic agents.
@en
P2093
Angela Zink
Anja Strangfeld
Christian Antoni
Erika Gromnica-Ihle
Joachim Listing
Jörn Kekow
Maria Stoyanova-Scholz
Matthias Schneider
Peter Herzer
P304
P356
10.1002/ART.21386
P577
2005-11-01T00:00:00Z